View in EDS

Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.

Saved in:
Bibliographic Details
Title: Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
Authors: Vergès B; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France. bruno.verges@chu-dijon.fr.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France. bruno.verges@chu-dijon.fr., Rouland A; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France., Bouillet B; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France., Pais de Barros JP; Université Bourgogne Europe, Inserm, UMS 058 BioSanD, DiviOmics, Dijon, France., Fourmont C; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France., Buffier P; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France., Jourdan T; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France., Vergas V; Université Bourgogne Europe, Inserm, UMS 058 BioSanD, DiviOmics, Dijon, France., Duvillard L; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Biochemistry, Dijon, France.
Source: Diabetologia [Diabetologia] 2026 Jul 17. Date of Electronic Publication: 2026 Jul 17.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42467086
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL<subscript>1</subscript>/VLDL<subscript>2</subscript> catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Vergès+B%22">Vergès B</searchLink>; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France. bruno.verges@chu-dijon.fr.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France. bruno.verges@chu-dijon.fr.<br /><searchLink fieldCode="AU" term="%22Rouland+A%22">Rouland A</searchLink>; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Bouillet+B%22">Bouillet B</searchLink>; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Pais+de+Barros+JP%22">Pais de Barros JP</searchLink>; Université Bourgogne Europe, Inserm, UMS 058 BioSanD, DiviOmics, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Fourmont+C%22">Fourmont C</searchLink>; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Buffier+P%22">Buffier P</searchLink>; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Endocrinology/Diabetology, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Jourdan+T%22">Jourdan T</searchLink>; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.<br /><searchLink fieldCode="AU" term="%22Vergas+V%22">Vergas V</searchLink>; Université Bourgogne Europe, Inserm, UMS 058 BioSanD, DiviOmics, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Duvillard+L%22">Duvillard L</searchLink>; Université de Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France.; Université de Bourgogne Europe, CHU Dijon Bourgogne, Department of Biochemistry, Dijon, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220006777%22">Diabetologia</searchLink> [Diabetologia] 2026 Jul 17. <i>Date of Electronic Publication: </i>2026 Jul 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>0006777 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0428 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220012186X%22">0012186X </searchLink><i>NLM ISO Abbreviation: </i>Diabetologia <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42467086
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00125-026-06810-6
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vergès B
      – PersonEntity:
          Name:
            NameFull: Rouland A
      – PersonEntity:
          Name:
            NameFull: Bouillet B
      – PersonEntity:
          Name:
            NameFull: Pais de Barros JP
      – PersonEntity:
          Name:
            NameFull: Fourmont C
      – PersonEntity:
          Name:
            NameFull: Buffier P
      – PersonEntity:
          Name:
            NameFull: Jourdan T
      – PersonEntity:
          Name:
            NameFull: Vergas V
      – PersonEntity:
          Name:
            NameFull: Duvillard L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 07
              Text: 2026 Jul 17
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0428
          Titles:
            – TitleFull: Diabetologia
              Type: main
ResultId 1